Replication deficient adenoviral TNF vector

Details Replication deficient adenoviral TNF vector Replication deficient adenoviral TNF vector

2000-06-27

2003-06-17

Priebe, Scott D. (Department: 1635)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S320100, C435S455000, C435S456000, C514S04400A

Reexamination Certificate

active

06579522

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
This invention pertains to a replication deficient adenoviral vector comprising a nucleic acid sequence coding for tumor necrosis factor (TNF), as well as a method of constructing and using such vector.
BACKGROUND OF THE INVENTION
Tumor necrosis factor (TNF), especially TNF-&agr;, is well-known for its anti-tumor effects and ability to act synergistically with radiation therapy. For example, certain replication deficient adenoviral vectors comprising the TNF-&agr; gene have been used in conjunction with radiation therapy to treat tumors in animals with some success (e.g., Hallahan et al.,
Nat. Med
., 1, 786-91 (1995)). The use of TNF as an anti-cancer/anti-tumor agent, however, has been limited by its severe systemic effects.
There remains a need for replication deficient TNF adenoviral vectors that have greater flexibility in their construction and use, and can provide greater success in the treatment of a tumor or cancer. The present invention provides such a vector, as well as a method of constructing such vector, and a therapeutic method involving the use of such vector.
BRIEF SUMMARY OF THE INVENTION
The present invention provides an adenoviral vector comprising (a) an adenoviral genome deficient in the early growth-4 (E4) region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a radiation inducible promoter operably linked to the nucleic acid sequence coding for TNF. This invention also provides an adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a spacer element of at least 15 base pairs in the E4 region of the adenoviral genome.
A method of producing an adenoviral vector also is provided by the present invention comprising (a) providing an adenoviral genome that is deficient in the E4 region of the adenoviral genome, (b) inserting a nucleic acid sequence coding for TNF into the adenoviral genome, and (c) inserting a radiation-inducible promoter into the adenoviral genome such that it is operably linked to the nucleic acid sequence coding for TNF. This invention further provides a method of treating a tumor or cancer in a host comprising administering an anti-cancer or anti-tumor effective amount of the adenoviral vector of the present invention to a host in need thereof.
The present invention may best be understood with reference to the accompanying drawings and in the following detailed description of the preferred embodiments.


REFERENCES:
patent: 4879226 (1989-11-01), Wallace et al.
patent: 5206152 (1993-04-01), Sukhatme
patent: 5571797 (1996-11-01), Ohno et al.
patent: 5612318 (1997-03-01), Weichselbaum et al.
patent: 5624830 (1997-04-01), Mullen et al.
patent: 5641755 (1997-06-01), Weichselbaum et al.
patent: 5652353 (1997-07-01), Fiers et al.
patent: 5763209 (1998-06-01), Sukhatme
patent: 5770581 (1998-06-01), Weichselbaum et al.
patent: 5817636 (1998-10-01), Weichselbaum et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5962424 (1999-10-01), Hallahan et al.
patent: 5968735 (1999-10-01), Stein et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6337338 (2002-01-01), Kozlowski et al.
patent: 197 47 718 (1999-05-01), None
patent: 0 486 526 (1990-08-01), None
patent: 0 869 180 (1998-10-01), None
patent: WO 92/11033 (1992-07-01), None
patent: WO 94/06916 (1994-03-01), None
patent: WO 95/06120 (1995-03-01), None
patent: WO 95/34671 (1995-12-01), None
patent: WO 96/27021 (1996-09-01), None
patent: WO 96/33746 (1996-10-01), None
patent: WO 97/12623 (1997-04-01), None
patent: WO 97/20051 (1997-06-01), None
patent: WO 98/00166 (1998-01-01), None
patent: WO 98/46779 (1998-10-01), None
patent: WO 98/46781 (1998-10-01), None
patent: WO 98/55622 (1998-12-01), None
patent: WO 99/00518 (1999-01-01), None
patent: WO 99/21589 (1999-05-01), None
patent: WO 99/23216 (1999-05-01), None
patent: WO 99/46371 (1999-09-01), None
patent: WO 99/47690 (1999-09-01), None
patent: WO 99/55831 (1999-11-01), None
patent: WO 99/65515 (1999-12-01), None
Karp et al. The Journal of Immunology, vol. 149, pp. 2076-2081, 1992.*
MA Morsy et al.,Proc.Natl.Acad.Sci USA, “An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene,” Jul. 1998, vol. 95, pp. 7866-7871.*
Y Manome et al., Human Gene Therapy, “Transgene Expression in Malignant Glioma Using a Replication-Defective Adenoviral Vector Containing the Egr-1 Promoter: Activation by Ionizing Radiation or Uptake of Radioactive Iododeoxyuridine,”Jul. 1998, 9:1409-1417.*
RG Vile et al., Gene Therapy, “Cancer gene therapy:hard lessons and new courses,” 2000, 7, pp. 2-8.*
J Gomez-Navarro et al., European Journal of Cancer, Gene Therapy for Cancer, Jun. 1999, vol. 35, No. 6, pp. 867-885.*
WF Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, pp. 25-30.*
IM Verma et al., Nature, “Gene therapy-promises, problems and prospects,” Sep. 1997, vol. 389, pp. 239-241.*
Walther et al., Viral Vector for Gene Transfer, Aug., Drugs 2000, vol. 60, No. 2, pp. 249-271.*
Mountain et al. Gene therpy: the first decade, Mar. 2000, TIBTECH, vol. 18, pp. 119-131.*
Kawashita et al., Regression of Hepatocellular Carcinoma in Vitro and in Vivo by Radiosensitizing Suicide Gene Therapy under the Inducible and Spatial Control of Radiation, Jun. 10, 1999, Human Gene Therapy, vol. 10, pp. 1509-1519.*
Mauceri et al., C. R. Acad. Sci. Series III, 322 (2-3), 225-228 (Feb. 1999).
Blankenstein et al.,J. Exp. Med., 173, 1047-1052 (1991).
Block et al.,Arch. Surg., 127, 1330-1334 (1992).
Brough et al.,J. Virol., 70(9), 6497-6501 (1996).
Eggermont et al.,Annals of Surgery, 224(6), 756-765 (1996).
Chung et al.,Cancer Gene Therapy, 5(6), 344-349 (1998).
Fiers et al.,Proceedings of the American Association for Cancer Research, 34, 581-582 (1993).
Fujii et al.,Blood, 93(12), 4328-4335 (1999).
Ginsberg et al.,Bulletin of the New York Academy of Medicine, 73(1), 53-58 (1996).
Hallahan et al.,Nature Medicine, 1(8), 786-791 (1995).
Hallahan et al.,Proceedings of ASCO, 15, p. 84, Abstract 3, (1996).
Hersh et al.,Gene Therapy, 2, 124-131 (1995).
Hu et al.,Cancer Research, 57, 3339-3343 (1997).
Isobe et al.,Biochem. Biomed. Res. Comm., 202(3), 1538-1542 (1994).
Jones et al.,Progress in Growth Factor Research, 1, 107-122 (1989).
Jones et al.,Cancer Surveys, 8(4), 817-836 (1989).
Koshita et al.,Int. J. Cancer, 63, 130-135 (1995).
Lejeune,European J. Cancer, 31A(6), 1109-1016 (1995).
Manusama et al.,Seminars in Surgical Oncology, 14, 232-237 (1998).
Marr et al.,Cancer Gene Therapy, 6(5), 465-474 (1998).
Marr et al.,Int. J. Onconology, 12, 509-515 (1998).
Marr et al.,Gene Therapy, 4, 1181-1188 (1997).
Martinet et al.,Am. J. Respir. Cell Mol. Biol., 6, 510-515 (1992).
Mauceri et al.,Proceedings of the American Association for Cancer Research, 37, p. 347, Abstract 2365, (1996).
Mauceri et al.,Cancer Research, 56, 4311-4314 (1996).
Mauceri et al.,Radiation Oncology Investigations, 5, 220-226 (1997).
Mulé,Proceedings of the American Association for Cancer Research, 34, 581 (1993).
Porter,Trends in Biotechnology, 9, 158-162 (1991).
Richards et al.,Annals of the New York Academy of Sciences, 762, 282-293 (1995).
Sato et al.,Cancer Research, 58, 1677-1683 (1998).
Seung et al.,Cancer Research, 55, 5561-5565 (1995).
Slesarev et al.,Medical Oncology, 15, 37-43 (1998).
Sparmann et al.,Int. J. Cancer, 59, 103-107 (1994).
Spriggs et al., in:Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, Chapter 25, 383-406 (Raven Press, Ltd., New York, NY, 1992).
Staba et al.,Gene Therapy, 5, 293-300 (1998).
Standiford et al.,Human Gene Therapy, 10, 899-909 (1999).
Wakabayashi et al.,Neruol. Med. Chir.(Tokyo),37, 739-746 (1997).
Weichselbaum et al.,Cancer Research, 54, 4266-4269 (1994).
Whartenby et al.,Drugs, 50(6), 951-958 (1995).
Wright et al.,Cancer Gene Therapy, 5(6), 371-379 (1998).

Affiliated with

Also associated with

Rating

Replication deficient adenoviral TNF vector does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Replication deficient adenoviral TNF vector, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Replication deficient adenoviral TNF vector will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3143998